Literature DB >> 19584686

Sustained BK viruria as an early marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum samples.

Nina Babel1, Juliane Fendt, Stoyan Karaivanov, Gantuja Bold, Steffen Arnold, Anett Sefrin, Evelyn Lieske, Martin Hoffzimmer, Mikalai Dziubianau, Nicole Bethke, Christian Meisel, Gerald Grütz, Petra Reinke.   

Abstract

BACKGROUND: BKV reactivation plays the causative role in the development of BKV-associated nephropathy (BKVAN). Because of the lack of effective therapy, early diagnosis of BKV reactivation is paramount for the prevention of BKVAN. Resting in uroepithelial cells, BKV is excreted first in urine before it can be detected in plasma. The present study analyzed predictive value of BK viruria for the development of BK viremia and its possible advantage for the early BKVAN prediction.
METHODS: Total of 4128 urine and serum samples obtained from renal transplant patients were analyzed for BKV positivity by real-time polymerase chain reaction in 433 patients in cross-sectional and in 233 patients in longitudinal manner, respectively. The prospective longitudinal analysis included seven measurements during the first posttransplant year.
RESULTS: A total of 7% and 19% patients were positive for BKV in serum and urine, respectively. Sustained BK viruria showed sensitivity of 100% and specificity of 94% for BK viremia and was associated with significantly higher level of BK load than the patients with transient viruria (P<0.01). Interestingly, BK viremia was preceded by BK viruria: the peak of viral load and number of positive patients appeared during the third and fifth posttransplant month for urine and serum, respectively. BKVAN diagnosed in 21.4% of patient with persistent BK viruria appeared 5 and 11 weeks after BKV reactivation in serum and urine, respectively, was detected.
CONCLUSION: Sustained BK viruria is a reliable marker allowing an early identification of patients at high risk of BKVAN development and therefore assure precocious therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584686     DOI: 10.1097/TP.0b013e3181aa8f62

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  23 in total

1.  A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients.

Authors:  Benjamin J D Weist; Patrizia Wehler; Linda El Ahmad; Michael Schmueck-Henneresse; Jason M Millward; Mikalai Nienen; Avidan U Neumann; Petra Reinke; Nina Babel
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

2.  Transient versus persistent BK viremia and long-term outcomes after kidney and kidney-pancreas transplantation.

Authors:  Nissreen Elfadawy; Stuart M Flechner; Jesse D Schold; Titte R Srinivas; Emilio Poggio; Richard Fatica; Robin Avery; Sherif B Mossad
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

Review 3.  BK polyomavirus infection and nephropathy: the virus-immune system interplay.

Authors:  Nina Babel; Hans-Dieter Volk; Petra Reinke
Journal:  Nat Rev Nephrol       Date:  2011-05-24       Impact factor: 28.314

4.  Early identification of renal transplant recipients with high risk of polyomavirus-associated nephropathy.

Authors:  K Teutsch; F Schweitzer; E Knops; R Kaiser; H Pfister; J Verheyen; H Göbel; T Cingöz; V Di Cristanziano
Journal:  Med Microbiol Immunol       Date:  2015-03-07       Impact factor: 3.402

Review 5.  Management of polyomavirus-associated nephropathy in renal transplant recipients.

Authors:  Dirk R J Kuypers
Journal:  Nat Rev Nephrol       Date:  2012-04-17       Impact factor: 28.314

6.  Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK.

Authors:  P Randhawa; D V Pastrana; G Zeng; Y Huang; R Shapiro; P Sood; C Puttarajappa; M Berger; S Hariharan; C B Buck
Journal:  Am J Transplant       Date:  2015-03-03       Impact factor: 8.086

7.  Putative episodes of T-cell-mediated rejection in patients with sustained BK viruria but no viremia.

Authors:  Kosuke Masutani; Ron Shapiro; Amit Basu; Henkie Tan; Toshiharu Ninomiya; Parmjeet Randhawa
Journal:  Transplantation       Date:  2012-07-15       Impact factor: 4.939

8.  Antigen-specific T cell responses to BK polyomavirus antigens identify functional anti-viral immunity and may help to guide immunosuppression following renal transplantation.

Authors:  A Chakera; S Bennett; S Lawrence; O Morteau; P D Mason; C A O'Callaghan; R J Cornall
Journal:  Clin Exp Immunol       Date:  2011-06-14       Impact factor: 4.330

9.  BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results.

Authors:  K L Hardinger; M J Koch; D J Bohl; G A Storch; D C Brennan
Journal:  Am J Transplant       Date:  2010-01-05       Impact factor: 8.086

Review 10.  Human polyoma viruses and disease with emphasis on clinical BK and JC.

Authors:  Raghavender Boothpur; Daniel C Brennan
Journal:  J Clin Virol       Date:  2010-01-08       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.